Short-Chain Peptides
ARA-290 Research Peptide
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix B domain of erythropoietin, designed to engage the innate repair receptor without erythropoietic signaling. Supplied lyophilized as a laboratory reference compound. For research use only.
$74.99 — 10mg vial
| Purity | ≥99% |
| Quantity | 10mg |
| Molecular Weight | 1257.35 g/mol |
| Sequence | Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| Category | Short-Chain Peptides |
| Latest batch tested | 08/14/26 |
ARA-290 in Research
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix B domain of erythropoietin to engage the innate repair receptor — the EPOR/CD131 heteromer — while avoiding the classical erythropoietic receptor. That separation of tissue-protective signaling from red-blood-cell stimulation is the core of its preclinical literature.
Supplied lyophilized at 10mg and ≥99% chromatographic purity with independent HPLC and MS batch verification.
Research Overview
- Investigated for selective engagement of the innate repair receptor (EPOR/CD131 complex)
- Studied for non-erythropoietic signaling separated from red blood cell stimulation
- Research into small-fiber neuropathy models and nociceptive signaling
- Explored for cytokine modulation and tissue-protective pathways in preclinical work
- Preclinical studies on corneal nerve fiber density and regeneration endpoints
Quality & Testing
Every ARA-290 batch is verified by independent third-party HPLC and mass-spectrometry testing, with a batch-specific certificate of analysis available on the COA page.
Laboratory Handling & Storage
Lyophilized peptides are supplied as a freeze-dried powder and are most stable stored cold (2–8°C), protected from light and moisture, in the original sealed vial. Under these conditions the research literature generally reports multi-year integrity for dry peptide material.
Once reconstituted in a laboratory setting, solutions are typically stored refrigerated and used within the window appropriate to the diluent and compound; repeated freeze–thaw cycles are avoided because they can promote aggregation. See our research overview on reconstitution and lyophilization for the underlying formulation science.
Frequently Asked Questions
What is ARA-290?
ARA-290 is a synthetic helix-B-derived peptide of erythropoietin studied for selective innate-repair-receptor (EPOR/CD131) engagement in preclinical tissue-protection models.
Why does non-erythropoietic signaling matter in this research?
Native erythropoietin's tissue-protective effects are entangled with red-blood-cell stimulation. ARA-290 was designed to engage only the repair receptor, letting researchers study cytoprotective signaling without the hematologic arm.
Is ARA-290 for human use?
No. ARA-290 is a research compound for laboratory use only — not an approved therapeutic.